CHWM has fallen roughly 44% over the last 30 days, sliding from about $5.43 to approximately $3.05, extending a decline since its October 2026 Nasdaq debut. The American Depositary Shares are newly listed, so the recent period largely reflects early post-listing price discovery in a thinly traded market.

XRPN has fallen roughly 44% over the last 30 days, sliding from a $15.26 close on October 14, 2026, to about $8.50 as the post-listing surge fully unwound. The decline follows a sharp, short-lived rally around the company's Nasdaq debut after it completed its business combination with Armada Acquisition Corp. II.

Starling Oncology (STLN) shares fell roughly 45% over the past 30 days, from about $6.51 to near $3.58, with most of the decline occurring in a single trading session. The selloff followed a third-quarter 2026 earnings miss, as the company posted a wider-than-expected loss of $0.13 per share versus a consensus estimate near $0.05.

Veracyte (VCYT) shares fell roughly 45.5% over the last 30 days, driven by a sharp selloff after the company's third-quarter 2026 earnings report. The stock plunged about 54% in a single session after management reset growth expectations for its flagship Decipher Prostate test and trimmed forward guidance.

Bicara Therapeutics (BCAX) declined roughly 43.6% over the trailing 30 days, driven chiefly by a single-session collapse on October 28, 2026. The selloff was triggered by positive Phase 3 data from Genmab for a competing head and neck cancer therapy, sharpening the competitive threat to Bicara's lead candidate.

BR Partners (BRBI) shares have declined roughly 50% over the past 30 days, sliding from about $15.30 to near $7.60 per American depositary share. The sharpest single-session drop followed the issuance of R$124.2 million in perpetual subordinated notes by a subsidiary, a move investors interpreted as a signal of dilution and liquidity risk.

MNTN, Inc. shares have fallen roughly 46.6% over the last 30 days, driven primarily by a sharp selloff following third-quarter 2026 results. On November 4, 2026, the company reported Q3 revenue of $80.3 million, below its own guidance range of $86 million to $89 million and below consensus estimates.

PicS N.V. (PICS) shares fell roughly 45% over the 30 days through mid-November 2026, sliding from about $13.22 to near $7.23. The sharpest declines followed Brazil's presidential runoff, when Luiz Inácio Lula da Silva's unexpected re-election triggered a broad selloff across Brazilian fintech names.

ZONE shares have declined roughly 48% over the last 30 days, from about $6.90 on a split-adjusted basis in mid-October to around $3.57 in mid-November. The move was compounded by a 1-for-60 reverse stock split that took effect on October 30, aimed at restoring compliance with NYSE American minimum-price requirements.

Exagen shares have dropped roughly 52% over the past 30 days, falling from about $8.42 on October 14, 2026, to around $4.05 intraday on November 13, 2026. The decline accelerated after third-quarter 2026 results, which showed a wider-than-expected loss and a sharp slowdown in AVISE CTD test-volume growth.

Iovance Biotherapeutics shares fell roughly 47% over the trailing 30 days, declining from about $14.21 to near $7.54 as of November 13, 2026. The sharpest single-day move came on October 29, 2026, when the stock dropped about 35% following updated Phase 2 IOV-LUN-202 lung cancer data for lifileucel.

XP Inc. shares have fallen roughly 50% over the last 30 days, dropping from about $30.49 to near $15.23 as a surprise election outcome triggered a sharp repricing of Brazilian assets. The stock plunged more than 50% intraday on October 26, 2026, touching a 52-week low of $13.78, after Brazil's presidential runoff overturned investor expectations of a rightward policy shift.

CCOI shares fell roughly 49% over the last 30 days, sliding from about $7.72 on October 14, 2026, to near $3.95, extending a prolonged decline. The drop accelerated after Cogent's third-quarter 2026 report, which showed a 4.4% year-over-year revenue decline to $231.2 million and a top-line miss versus consensus.

Faeth Therapeutics (FTH) shares have fallen roughly 48% over the last 30 days, from about $20.00 in mid-October to approximately $10.31. The sharpest decline came after the company's November 9, 2026 Phase 2 PIK-201 data readout, which investors judged as falling short of expectations versus emerging antibody-drug conjugates.

Meridian Holdings (MRDN) has fallen roughly 48% over the trailing 30 days, sliding from about $11.00 to near $5.69 per share. The sell-off accelerated after third-quarter 2026 results were reported on November 10, 2026, with a roughly 24% single-session drop on the earnings release.

DJTWW, the publicly traded warrants of Trump Media & Technology Group, have fallen roughly 55% in the last 30 days, from about $5.32 in early October to around $2.40 in mid-November. The decline closely tracked a sharp sell-off in the underlying common stock ( DJT ), which dropped about 24.5% in a single session on November 4 after Democrats swept control of both chambers of Congress in the U.S. midterm elections.

Corvex, Inc. (MOVE) — formerly Movano Health — fell roughly 60% over the trailing 30 days, sliding from about $8.89 to the low-single-digit range near $3.55. The decline accelerated after third-quarter 2026 results reported on Nov. 12 missed expectations and the company flagged a potential goodwill impairment tied to its March 2026 Corvex merger.

AMTD IDEA Group (AMTD) shares fell roughly 64% over the past 30 days, declining from a close near $34.80 to about $12.50, extending a steep multi-month selloff. The decline followed the company's plan to implement a one-for-60 reverse ADS ratio change, effective around October 19, 2026, aimed at regaining compliance with NYSE minimum-price listing rules.

Bright Minds Biosciences (DRUG) shares have fallen roughly 54.7% over the past 30 days, from about $50.71 in mid-October to about $22.96 in mid-November. The decline was driven primarily by a U.S. Food and Drug Administration (FDA) partial clinical hold on the planned Phase 2 BMB-101 trial in developmental and epileptic encephalopathies (DEE), announced on November 2, 2026.

Atlas Energy Solutions shares have fallen roughly 51% over the last 30 days, sliding from about $11.07 at the October 14 close to near $5.38. The sell-off accelerated after Q3 2026 results reported on November 2, 2026, which included a $45.1 million net loss and an adjusted net loss of $0.36 per share.